Douglas Falk

Doug Falk, MS, co-founded and joined Vita Therapeutics, Inc. as Chief Executive Officer in 2019. Prior, he spent six years in the investment world with a particular focus in biotechnology at Brown Advisory, where he was a principal, Merrill Lynch, and Lazard. He was also involved in the formation of Regron Therapeutics, a Johns Hopkins spin, and currently sits on the board of directors. In addition to his work at Vita, Doug is actively involved in the venture capital scene, serving as a venture partner for Riptide Ventures. He received his MS from Johns Hopkins University in biotechnology and his BA from Goucher College in economics and business management.